Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy
- 31 July 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 188 (1), 58-62
- https://doi.org/10.1016/j.juro.2012.03.007
Abstract
Purpose: We assessed the impact of hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer on the long-term recurrence rate. Materials and Methods: Long-term followup was assessed in 551 participants enrolled in a prospective, randomized study of fluorescence cystoscopy for Ta or T1 urothelial bladder cancer. In the original study 280 patients in the white light cystoscopy group and 271 in the fluorescence cystoscopy group were followed with cystoscopy for 3, 6 and 9 months after initial resection or until recurrence. A study extension protocol was done for long-term followup of these patients. Results: Followup information was obtained for 261 of the 280 patients (93%) in the white light group and 255 of the 271 (94%) in the fluorescence group. Median followup in the white light and fluorescence groups was 53.0 and 55.1 months, and 83 (31.8%) and 97 patients (38%) remained tumor free, respectively. Median time to recurrence was 9.4 months in the white light group and 16.4 months in the fluorescence group (p = 0.04). The intravesical therapy rate was similar in the 2 groups (46% and 45%, respectively). Cystectomy was done in 22 of 280 cases (7.9%) in the white light group and in 13 of the 271 (4.8%) in the fluorescence group (p = 0.16). Conclusions: Hexaminolevulinate fluorescence cystoscopy significantly improves long-term bladder cancer time to recurrence with a trend toward improved bladder preservation.This publication has 15 references indexed in Scilit:
- Editorial CommentJournal of Urology, 2010
- Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder CancerJournal of Urology, 2010
- Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in SwedenScandinavian Journal of Urology and Nephrology, 2009
- Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic IssuesEuropean Urology Supplements, 2008
- A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder CancerJournal of Urology, 2007
- A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter StudyJournal of Urology, 2007
- IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDYJournal of Urology, 2005
- Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence CystoscopyJournal of Urology, 2004
- Hexyl Aminolevulinate Fluorescence Cystoscopy: A New Diagnostic Tool for Photodiagnosis of Superficial Bladder Cancer—A multicenter studyJournal of Urology, 2003
- Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acidUrology, 1994